Immunotherapy plus chemo shows promise for rare sinus cancer
NCT ID NCT05925491
First seen Apr 17, 2026 · Last updated May 24, 2026 · Updated 8 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery can shrink advanced sinonasal tumors and reduce side effects. About 28 adults with a rare, aggressive sinus cancer will receive the combination, then surgery, followed by more pembrolizumab. The goal is to see if this approach improves tumor response and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SINONASAL UNDIFFERENTIATED CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Clinici Scientifici Maugeri
RECRUITINGPavia, Lombardy, 27100, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.